Prophylactic cranial irradiation (PCI) for SCLC offers a consistent reduction in the incidence of brain metastases at the cost of measurable toxicity to neurocognitive function and quality of life, in the setting of characteristic pathologic changes to the brain. The sequelae of PCI have historically been justified by the perception of an overall survival advantage specific to SCLC. This rationale has now been challenged by a randomized trial in extensive-stage SCLC demonstrating equivalent progression-free survival and a trend toward improved overall survival with PCI omission in the context of modern magnetic resonance imaging (MRI) staging and surveillance. In this article, we critically examine the randomized trials of PCI in extensive-stage SCLC and discuss their implications on the historical data supporting PCI for limited-stage SCLC from the pre-MRI era. Further, we review the toxicity of moderate doses of radiation to the entire brain that underlie the growing interest in active MRI surveillance and PCI omission. Finally, the evidence supporting prospective investigation of radiosurgery for limited brain metastases in SCLC is reviewed. Overall, our aim is to provide an evidence-based assessment of the debate over PCI versus active MRI surveillance and to highlight the need for contemporary trials evaluating optimal central nervous system management in SCLC.
Introduction
Prophylactic cranial irradiation (PCI) for SCLC was introduced in the pre-magnetic resonance imaging (MRI) era of the 1970s in response to high rates of brain metastases (BMs) and a regard for the central nervous system (CNS) as a pharmacologic sanctuary. 1 Although reductions in BMs were evident in early studies, concerns regarding the cost of PCI in terms of neurocognitive toxicity and quality of life (QoL) emerged. [2] [3] [4] [5] [6] [7] [8] In 1999, a meta-analysis revealed a 5% overall survival (OS) advantage with PCI in trials of primarily limited-stage (LS)-SCLC. 9 With data to support an OS advantage in hand, the adverse effects were considered justifiable and PCI was elevated to a component of standard management. 10 In 
Key Differences in the Randomized Trials of PCI in ES-SCLC
The divergent OS outcomes in the EORTC 11 and Japanese 12 trials in ES-SCLC are likely explained by important differences in CNS staging and surveillance ( Fig. 1) . 13 The EORTC trial did not require CNS imaging before randomization, and subsequent imaging was acquired only for neurologic symptoms. The Japanese trial mandated CNS imaging before randomization and at 3, 6, 9, 12, 18, and 24 months in both arms. Therefore, whereas the EORTC trial included an arm of PCI omission, the Japanese trial included PCI omission with active MRI surveillance.
The differences in CNS staging may have been consequential. BMs at diagnosis in SCLC are identifiable in approximately 10% of patients using computed tomography and up to 25% using more sensitive brain MRI.
14 BMs can also become evident after initial therapy; one retrospective analysis reported new BMs in one-third of patients after initial therapy and before planned PCI. 15 Thus, the literature indicates that a meaningful but unquantified number of patients in the EORTC trial would have had asymptomatic BMs at enrollment and, in reality, these patients were randomized to early therapeutic (rather than prophylactic) radiation versus observation of BMs until the time of neurologic symptoms.
It could be reasonably argued that the inclusion of patients with macroscopic BMs in the EORTC trial might not have altered the impact of radiation, given that multiple trials excluding patients with SCLC have failed to show an OS advantage with whole-brain radiation (WBRT) for BMs. [16] [17] [18] [19] [20] [21] A strong counterargument, however, is that PCI has historically been justified by the perception of an OS advantage with brain radiation specific to the SCLC histologic type and not seen, for example, in NSCLC. [22] [23] [24] Under this premise, it is rational to expect that the benefits of treating subclinical BMs present in an unknown percentage of patients (i.e., PCI) would, in fact, be magnified in an enriched subset where all patients have BM.
The active MRI surveillance in the Japanese trial, as compared with the reactive imaging for neurologic symptoms in the EORTC trial, likely influenced the timing and percentage of patients eligible for salvage therapy. In the Japanese trial, of the patients in the active surveillance alone arm in whom BMs developed, 83% received salvage brain radiation. In the EORTC trial, of the patients in the observation arm in whom BMs developed, 59% received salvage radiation. Thus, a remarkable 41% with symptomatic BMs in the observation arm of the EORTC trial did not receive radiation. Although it is not possible to know all the factors underlying decisions to offer salvage treatment, it is plausible that delayed identification of BMs in the EORTC trial may have compromised performance status and reduced the percentage of patients eligible for salvage therapy, with a resulting decrement in OS. This possibility is further supported by the observation that patients in the PCI omission arm of the EORTC trial received less salvage chemotherapy, whereas the opposite was true in the Japanese trial.
In addition to CNS staging and surveillance, a third consideration would be for potential differences in the efficacy of therapies in Japanese and Western populations. For example, irinotecan-platinum significantly improved OS over that with etoposide-platinum in a Japanese ES-SCLC trial, 25 whereas OS differences were either smaller or not observed in subsequent Western trials, [26] [27] [28] [29] with speculation that pharmacogenomics might underlie the differences. 28, 29 As a result, irinotecan-platinum was delivered in 38% of patients in the Japanese PCI trial 12 but not mentioned in the earlier EORTC trial. 30 The impact of these chemotherapeutic differences on the efficacy of PCI is unknown 31, 32 ; however, this example highlights the interest in replicability of trial data in distinct racial populations. 33 In the context of these concerns, the similar magnitude of the reduction in BMs with PCI in the Japanese trial (12-month rate 33% versus 59% [p < 0.001]) as compared with in the EORTC trial (12-month rate 15% versus 40% [p < 0.001]) does provide some important support to the generalizability of the Japanese data. Overall, although the EORTC and Japanese trials were both concerned with PCI in ES-SCLC, the critical differences in CNS staging and surveillance indicate that these trials were asking distinct questions: PCI vs reactive imaging for neurologic symptoms in the EORTC trial, where PCI improved OS; and PCI vs active MRI surveillance in the Japanese trial, where PCI did not improve OS and may have even been harmful.
Strengths and Limitations of the PCI Data in LS-SLCLC
The modern design and results of the Japanese ES-SCLC trial 12 have important implications for the historical data supporting PCI in LS-SCLC. The landmark meta-analysis by Aupérin et al. 9 analyzed 987 individual patient records from seven randomized trials enrolling patients from 1977 to 1995, including two trials that were unpublished. [34] [35] [36] [37] [38] [39] Overall, a 25.3% absolute reduction in BMs was observed at 3 years (58.6% versus 33.3%), with a corresponding 5.4% improvement in 3-year OS (20.7% versus 15.3%). 9 The timing of PCI in relation to initial therapy was heterogeneous and the PCI doses ranged from 8 Gy in a single fraction to 40 Gy over 20 fractions. Most of the patients had LS-SCLC (86%), and all were required to have had a complete response to initial therapy as defined by their individual trials. Importantly, as it relates to the aforementioned EORTC and Japanese trial designs, all studies were in the pre-MRI era and brain computed tomography requirements were limited to the evaluation of symptoms in more than half of the patients analyzed (Table 1) .
In 2001, Meert et al. 40 reported a systematic review of 12 randomized trials evaluating PCI versus no PCI and including 1547 patients. [35] [36] [37] [38] [41] [42] [43] [44] [45] [46] [47] [48] In a subgroup analysis of four pre-MRI era trials that required a complete response to upfront therapy, [35] [36] [37] [38] each of which was included in the aforementioned metaanalysis by Aupérin et al., 9 a similar OS advantage with PCI was demonstrated (hazard ratio ¼ 0.82, 95% confidence interval: 0.71-0.96). 40 However, no OS benefit with PCI was observed in the primary analysis including all trials or the subgroup analysis of patients with LS-SCLC.
To our knowledge, no individual randomized trial has demonstrated a significant OS advantage with PCI for LS-SCLC. The one randomized trial to show a significant OS difference with PCI in LS-SCLC was the Intergroup trial, which reported inferior survival with higher-dose (36 Gy) compared with lower-dose (25 Gy) radiation (2-year OS of 37% versus 42% [p ¼ 0.05]). 49 The decrement in OS that was observed with higher-dose radiation cannot be used to invalidate the role of PCI, as there are notable examples at other disease sites in which lower doses of radiation have been associated with superior OS. 50, 51 However, the results of the Intergroup trial 49 do characterize a potential for harm associated with radiation to the entire brain, which has also now been suggested by the Japanese trial in ES-SCLC 12 and a meta-analysis of randomized trials of WBRT. 52 A number of retrospective analyses have characterized correlations between PCI and OS; although, causal inferences regarding PCI and survival outside the context of randomized trials are largely precluded by the selection and indication biases that drive PCI delivery. 53, 54 Overall, many of the criticisms of the EORTC trial 11 regarding suboptimal CNS staging and surveillance that informed the design of the Japanese trial in ES-SCLC 12 would also appear to apply to the pre-MRI metaanalysis data supporting PCI in LS-SCLC (Table 1) . Currently, there are no randomized data assessing PCI versus active MRI surveillance in LS-SCLC, and in the context of this modern comparison the potential impact of PCI on survival is unknown.
QoL, Cognition, and the Risk-Benefit Assessment
If the reduction in BMs with PCI was associated with improved QoL and sustained cognition, there would be clinical justification for delivery in all patients with SCLC even without an OS advantage. Unfortunately, PCI has been associated with measurable declines in cognitive function and QoL in contemporary trials, with effects that appear comparable to those of WBRT for BM. Indeed, approximately 40% of patients with LS-SCLC do not receive PCI, primarily because of concerns over toxicity. 55, 56 A pooled analysis of the Radiation Therapy Oncology Group (RTOG) 0212 and 0214 trials 57 reported inferior performance on cognitive testing and a more than threefold increase in patient-reported cognitive dysfunction with PCI at both 6 and 12 months (Fig. 2) . RTOG 0214 reported a significant decline in performance on the Hopkins Verbal Learning Test at 3, 6, and 12 months with PCI versus with observation. 58 RTOG 0212 demonstrated increased cognitive toxicity with higher PCI dose, and the Intergroup and RTOG 0212 trials observed greater declines in QoL and cognition after PCI with older patient age. 59, 60 Recognition of the cognitive sequelae of PCI has led to the ongoing cooperative randomized phase II/III trial NRG CC003, which is evaluating PCI with and without hippocampal avoidance techniques (ClinicalTrials.gov identifier NCT02635009). The primary end point of the phase III component of this trial is to determine whether hippocampal avoidance PCI can reduce the incidence of cognitive deterioration on the Hopkins Verbal Learning Test at 6 months versus with standard PCI.
The EORTC randomized trial of PCI versus observation for ES-SCLC prospectively evaluated patientreported QoL. 61 Because of a median OS of only 6 months and poor compliance with questionnaires over time, the analysis was primarily limited to short-term QoL assessment. Inferior QoL scores with PCI were observed during the first 3 months for all prespecified end points, with the differences reaching significance for fatigue and hair loss and trends for global health, cognitive, emotional, and role functioning. Severe reductions in QoL (20 points on a 100-point scale) were more common with PCI in all domains. Exploratory analyses demonstrated significant reductions in QoL scores with PCI for nausea and vomiting, appetite, constipation, future uncertainty, headaches, motor dysfunction, and leg weakness. Most of the observed differences were no longer identifiable by 6 months in the EORTC trial and, in general, the long-term QoL effects of PCI delivery versus PCI omission in SCLC are not well characterized. In one contemporary randomized trial in NSCLC, the RTOG 0214, no significant differences in QoL were reported at 12 months, although a trend toward inferior cognitiverelated QoL was observed. 58 In light of the similarities in delivery between PCI and WBRT, there is also a preponderance of relevant data from the randomized WBRT literature characterizing the deleterious neurocognitive effects and longerterm impact on QoL of radiation to the entire brain. [17] [18] [19] 62 Moderate doses of radiation to the entire brain, which are common to both WBRT and PCI, are also associated with characteristic anatomic and pathophysiologic sequelae, including progressive white matter changes (Fig. 3) , demyelination, cortical atrophy, endothelial damage, diminished capillary density, blood-brain barrier disruption, proinflammatory and oxidative stress, and impaired neurogenesis. [63] [64] [65] [66] [67] [68] The consistency of these clinical and pathophysiologic findings, in the absence of an OS benefit from WBRT, has changed the landscape of management of BMs across most histologic types in favor of avoiding WBRT when patients can be safely managed with radiosurgery alone. 69, 70 Clear parallels exist between PCI and WBRT regarding the risk-benefit considerations for QoL, cognition, and survival. If PCI does not in fact improve OS in the modern era of MRI staging, surveillance, and salvage therapy options-as is suggested by the Japanese trial for ES-SCLC 12 and is now an open question for LS-SCLC-there is meaningful precedent from the WBRT literature for a reappraisal of the role of PCI in contemporary practice. 69, 70 Radiosurgery and SCLC Looking forward, by avoiding compulsory radiation to the entire brain and identifying more patients with limited BMs, increasing adoption of active surveillance should open the door to further investigation of radiosurgery as a truly first-line therapy in selected patients with SCLC. 71 The historical role of PCI has almost certainly contributed to a more resilient acceptance of WBRT for limited BMs in SCLC despite the transition toward radiosurgery for limited BMs in most other histologic types. 69, 70 Clinical impediments to radiosurgery in SCLC also arise from underlying concerns regarding the potential for subsequent diffuse CNS progression and increased neurologic mortality, as well as from the need for more CNS salvage therapy. 72 A number of series have reported encouraging outcomes with radiosurgery for recurrent BMs in SCLC after Figure 3 . White matter changes on magnetic resonance imaging (MRI) in patients with lung cancer after radiation therapy to the entire brain. Analysis of 68 patients with lung cancer with brain metastases, including 37 treated with whole-brain radiation and stereotactic radiosurgery (SRS) and 31 control patients treated with SRS alone. Image review was blinded to the treatment cohort. The median and mode whole-brain radiation dose was 30 Gy over 10 fractions (range 20-37.5 Gy). Adapted with permission from Monaco et al. 63 PCI or WBRT. [73] [74] [75] [76] [77] [78] [79] Additionally, there is a growing body of literature supporting to the viability first-line radiosurgery in selected patients with SCLC in the absence of prior PCI or WBRT, with low reported rates of neurologic mortality and outcomes comparable to those of patients with NSCLC managed with the same approach. [78] [79] [80] [81] [82] [83] Notably, Serizawa et al. analyzed 34 patients with SCLC and 211 patients with NSCLC receiving first-line radiosurgery and reported no differences in local tumor control, distant brain control, OS, or neurologic mortality. 82 Ozawa et al. reported on 94 patients with LS-SCLC treated with a strategy of PCI omission, MRI surveillance, and radiosurgery as the preferred first-line therapy for BMs, with OS equivalent to that of patients treated with upfront PCI. 81 In addition, approximately 20% of patients in the active surveillance arm of the Japanese ES-SCLC trial who required radiation were reported to have undergone first-line radiosurgery. 84 These data challenge the historical dogma that all BMs from SCLC require WBRT and suggest that prospective investigation of upfront radiosurgery for selected patients with limited BMs is warranted. For those considering radiosurgery, MRI surveillance and higher rates of distant brain recurrences would likely need to be viewed as accepted trade-offs, rather than a failure of approach, for the benefits of avoiding the sequelae of PCI or WBRT, which are similar to accepted radiosurgery paradigms in other histologic types. 18, 20, 69, 70 Conclusions and Future Directions PCI offers a clear reduction in BMs from SCLC 9, 11, 12 at the cost of measurable declines in cognition and QoL, 57, 58, 60, 61 which appear similar to the profile of WBRT. [17] [18] [19] 62 The sequelae of PCI have historically been justified by an OS advantage observed in studies with suboptimal or absent CNS staging and surveillance, which were primarily conducted in the pre-MRI era. 9, 11 The survival advantage with PCI has now been challenged in a trial including modern MRI staging, surveillance, and salvage therapy, in which the reductions in BMs with PCI did not translate into an OS advantage and in which PCI was, provocatively, associated with a trend toward inferior OS. 12 Controversy over PCI is hardly a new phenomenon; the value of PCI was widely debated for nearly three decades after its proposal in the early 1970s, 1-8 until publication the meta-analysis by Aupérin et al. in 1999. Given the enduring concerns over toxicity, PCI is also unlikely to be a permanent answer to SCLC's CNS predilection. Challenges to PCI could always arise from the emergence of systemic therapies with enhanced CNS activity or the utilization of technology to allow early, effective treatment in patients with development of BMs-and the latter may have materialized in the MRI surveillance paradigm put forth by the Japanese trial in ES-SCLC. 12 Clinicians are now faced with the challenge of reconciling the historical data supporting PCI 9,11 with the conflictingly results of a single modern randomized trial. 12 Understanding the differences in staging and surveillance in the Japanese trial 12 versus in prior studies is therefore highly relevant to clinical practice. In cases in which PCI is omitted, patients should now be monitored with regular MRI imaging, and guideline statements will need to be updated to reflect appropriate surveillance paradigms. Moreover, given the relatively high incidence of BMs even after PCI (2-year rates of 20%-45% in ES-SCLC 11, 12 and 20%-35% in LS-SCLC 9, 49 ), a minimum of annual MRI surveillance would appear justifiable for these patients as well. Shared decision making is now essential, as many patients will prefer to avoid PCI in favor of surveillance, whereas routine MRIs may not always be feasible or the reduction in BMs with PCI may outweigh concerns over toxicity for others. 34, 85 The conflicting data on PCI in ES-SCLC and concerns regarding the limitations and contemporary relevance of the pre-MRI data on PCI for LS-SCLC highlight the need for modern trials evaluating optimal CNS management in SCLC. A randomized trial of PCI versus active MRI surveillance in LS-SCLC is now clearly needed given the absence of data on this vital comparison. For those who wish to avoid PCI, the Japanese ES-SCLC trial provides randomized evidence establishing active MRI surveillance as a viable option; however, further prospective data addressing PCI versus active surveillance in ES-SCLC may be necessary to resolve the equipoise generated by the results of the Japanese 12 and EORTC 11 trials. Prospective data on radiosurgery are also needed to evaluate the potential role and selection of patients with SCLC who might be safely managed with this approach. Finally, rigorous evaluations of neurocognitive function and QoL will remain essential to the risk-benefit assessments of evolving CNS paradigms for patients with SCLC.
